Iovance Biotherapeutics Hits Day High with 11.08% Surge in Stock Price

Iovance Biotherapeutics, Inc. has experienced a significant uptick in its stock performance, gaining 11.08% on May 22, 2026. The stock reached an intraday high of USD 4.19, marking a notable achievement for the small-cap company operating within the Pharmaceuticals & Biotechnology sector. Over the past week, Iovance has shown a robust performance with a 19.13% increase, significantly outpacing the S&P 500's 0.88% gain during the same period. The company's one-month performance stands at 16.43%, again surpassing the S&P 500's 4.7%. In terms of longer-term performance, Iovance has demonstrated a remarkable 134.86% increase over the past year, compared to the S&P 500's 27.93%. Year-to-date, the stock has risen by 50.55%, while the S&P 500 has gained 9.17%. However, it is important to note that over three, five, and ten-year periods, Iovance's performance has lagged behind the broader market. With a market capitalization of USD 1,664 million, Iovance continues to navigate the competitive landscape of its industry, reflecting both its potential and the challenges it faces.